What medication is typically administered for increased intracranial pressure (ICP)?

Mannitol is the correct choice for managing increased intracranial pressure (ICP) because it acts as an osmotic diuretic. By drawing water out of the brain tissue and into the bloodstream, Mannitol effectively reduces the volume of intracranial fluid, which can help alleviate pressure on the brain. This property is particularly beneficial in conditions like traumatic brain injury or hemorrhage, where rapid reduction of ICP is critical to preventing further neurological damage.

The mechanism of action of Mannitol is based on its ability to create a gradient that promotes the movement of water, thus reducing cerebral edema and providing neuroprotective effects. As it influences fluid dynamics within the cranial cavity, it can support better cerebral perfusion and ultimately improve outcomes for patients experiencing elevated ICP.

Considering the other medications listed: Furosemide is a loop diuretic that can help reduce fluid overload, but it is not specifically indicated for ICP. Alteplase is a thrombolytic agent used to dissolve blood clots, primarily in the context of stroke or myocardial infarction, and does not have a role in managing ICP. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that can help manage pain and inflammation but does not target the underlying issues